Mesoblast Limited Says FDA Grants Orphan Drug Designation For Use Of Proprietary Stem Cells In Bone Marrow Transplants Australia's regenerative
medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced that the United States Food and Drug Administration (FDA) has granted an orphan drug designation for the use of the patented adult stem cell technology in patients undergoing bone marrow transplantation. The FDA awarded Mesoblast's US-based sister company, Angioblast Systems Inc.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
